NASDAQ:HOTH Hoth Therapeutics (HOTH) Stock Price, News & Analysis $0.83 +0.02 (+2.45%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.83▼$0.9050-Day Range$0.81▼$1.2252-Week Range$0.72▼$3.37Volume942,278 shsAverage Volume522,229 shsMarket Capitalization$4.47 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get Hoth Therapeutics alerts: Email Address Hoth Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside379.2% Upside$4.00 Price TargetShort InterestHealthy1.07% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 14 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.40) to ($0.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.07 out of 5 stars 3.5 Analyst's Opinion Consensus RatingHoth Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageHoth Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Hoth Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.07% of the float of Hoth Therapeutics has been sold short.Short Interest Ratio / Days to CoverHoth Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hoth Therapeutics has recently decreased by 25.36%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldHoth Therapeutics does not currently pay a dividend.Dividend GrowthHoth Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HOTH. Previous Next 2.0 News and Social Media Coverage News SentimentHoth Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Hoth Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for HOTH on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hoth Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders10.56% of the stock of Hoth Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.08% of the stock of Hoth Therapeutics is held by institutions.Read more about Hoth Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Hoth Therapeutics are expected to grow in the coming year, from ($1.40) to ($0.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Hoth Therapeutics is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hoth Therapeutics is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHoth Therapeutics has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Hoth Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIHow a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…Click now to see for yourself what $0.25 Cent Trades is all about About Hoth Therapeutics Stock (NASDAQ:HOTH)Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.Read More HOTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HOTH Stock News HeadlinesJuly 26 at 9:52 AM | markets.businessinsider.comBuy Rating Affirmed for Hoth Therapeutics on Strategic Partnerships and Promising Alzheimer’s Treatment AdvancesJuly 25 at 1:13 AM | americanbankingnews.comQ2 2024 EPS Estimates for Hoth Therapeutics, Inc. (NASDAQ:HOTH) Boosted by AnalystJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! July 24 at 2:31 PM | theglobeandmail.comMicro Cap Already Off To The Races At The BellJuly 24 at 11:22 AM | investorplace.comWhy Is Hoth Therapeutics (HOTH) Stock Moving Today?July 24 at 9:31 AM | markets.businessinsider.comHoth Signs Deal With LTS Therapy To Develop & Manufacture HT-ALZ Oral Film Prot; Stock UpJuly 24 at 6:30 AM | prnewswire.comHoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's TreatmentJuly 23 at 7:36 AM | americanbankingnews.comHoth Therapeutics (NASDAQ:HOTH) Receives "Buy" Rating from HC WainwrightJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! July 22, 2024 | markets.businessinsider.comHoth Therapeutics’ Expansion and AI Integration Bolster Buy RatingJuly 16, 2024 | prnewswire.comHoth Therapeutics Expands Clinical Trial for Cancer PatientsJune 10, 2024 | prnewswire.comHoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug DiscoveryMay 23, 2024 | finance.yahoo.comHoth Therapeutics, Inc. (HOTH) Stock Price, News, Quote & History - Yahoo FinanceMay 15, 2024 | investorplace.comHOTH Stock Earnings: Hoth Therapeutics Misses EPS for Q1 2024May 1, 2024 | prnewswire.comHoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024April 12, 2024 | msn.comHoth Therapeutics files to sell 5.03M shares of common stock for holdersApril 2, 2024 | msn.comThe Brickyard, Carlisle to welcome popular rock band Elias T HothMarch 27, 2024 | prnewswire.comHoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross ProceedsSee More Headlines Receive HOTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hoth Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HOTH CUSIPN/A CIK1711786 Webwww.hoththerapeutics.com Phone(646) 756-2997FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+367.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,840,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-83.04% Return on Assets-73.34% Debt Debt-to-Equity RatioN/A Current Ratio13.13 Quick Ratio13.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.03 per share Price / Book0.42Miscellaneous Outstanding Shares5,360,000Free Float4,793,000Market Cap$4.59 million OptionableNot Optionable Beta0.80 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Robb Knie (Age 55)President, CEO & Chairman Comp: $844.01kMr. David S. Briones (Age 48)Chief Financial Officer Ms. Hayley SpringerExecutive Vice President of OperationsKey CompetitorsAzurRx BioPharmaNASDAQ:AZRXGuardion Health SciencesNASDAQ:GHSICara TherapeuticsNASDAQ:CARATherapeuticsMDNASDAQ:TXMDJanOneNASDAQ:JANView All Competitors HOTH Stock Analysis - Frequently Asked Questions How have HOTH shares performed this year? Hoth Therapeutics' stock was trading at $1.44 at the beginning of 2024. Since then, HOTH stock has decreased by 42.0% and is now trading at $0.8347. View the best growth stocks for 2024 here. How were Hoth Therapeutics' earnings last quarter? Hoth Therapeutics, Inc. (NASDAQ:HOTH) announced its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by $0.03. When did Hoth Therapeutics' stock split? Hoth Therapeutics shares reverse split on Wednesday, October 26th 2022. The 1-25 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Hoth Therapeutics IPO? Hoth Therapeutics (HOTH) raised $8 million in an initial public offering (IPO) on Friday, February 15th 2019. The company issued 1,300,000 shares at a price of $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO. How do I buy shares of Hoth Therapeutics? Shares of HOTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Hoth Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hoth Therapeutics investors own include Citius Pharmaceuticals (CTXR), Ocugen (OCGN), Fulcrum Therapeutics (FULC), Heat Biologics (HTBX), Tonix Pharmaceuticals (TNXP), AIM ImmunoTech (AIM) and Aytu BioPharma (AYTU). This page (NASDAQ:HOTH) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hoth Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hoth Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.